Assessment of Complete Remission Rate in Patients with Acute Myeloid Leukemia Undergoing 7+3 Induction Chemotherapy: Remission Rates in Acute Myeloid Leukemia Patients

Nazish Mehboob; Asma Khan; Attiya Munir; Muhammad Tahir; Amanat Ali; Sameer Ahmed

doi:10.54393/pjhs.v5i06.1570

Authors

Nazish Mehboob Department of Oncology, Rawal Institute of Health Sciences, Islamabad, Pakistan
Asma Khan Department of Pharmacology, Rawalpindi Medical University, Rawalpindi, Pakistan
Attiya Munir Department of Pharmacology, Rawalpindi Medical University, Rawalpindi, Pakistan
Muhammad Tahir Department of Pharmacology, Mekran Medical College, Turbat, Pakistan
Amanat Ali Department of Pharmacology, Hazrat Bari Imam Sarkar, Medical and Dental College, Islamabad, Pakistan
Sameer Ahmed Department of Pharmacology, Rawal Institute of Health Sciences, Islamabad, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v5i06.1570

Keywords:

Acute Myeloid Leukemia, Induction Chemotherapy, Complete Remission, Malignancy

Abstract

Acute leukemia is a fast-growing, overpopulated clone of immature proliferating cells that largely predominate in the bone marrow and have the capacity to prolong life indefinitely. Upon inspection and cytologic assessment of bone marrow or peripheral blood, the cells demonstrate quantified uncertainties. Objective: To determine the frequency of complete remission after induction 7+3 chemotherapy in patients with acute myeloid leukemia. Methods: The nature of this study was cross sectional study at Department of Oncology, Pakistan Institute of Medical Sciences, and Islamabad from 26 November, 2022 to 26 May, 2023. The hospital’s laboratory fulfilled the complete blood count and provided the confirmed baseline bone marrow biopsy reports. All patients who were admitted received treatment with a 7+3 regime, a standard treatment protocol for all the adolescents and adults admitted. Every patient was prescribed for 7+3 induction therapy regimen which consists of 200 mg/m² cytarabine for seven days and idarubicin for three days, 12 mg/m² on the 1st, 3rd and 5th day. Results: The complete remission estimated turns out to be 61.1% and rest need further treatment. The average age of the patients was 48.56 ± 6.91 years. The mean BMI stood at 24.46 ± 1.49 kg/m². gender wise, 74 were male and 21 were female. Our mean CR was 61.1% that is 58 participants all the complete demographic is available. Conclusions: This study revealed a Complete Remission (CR) rate of 61.1% in patients with AML undergoing 7+3 induction chemotherapy. However, our findings suggest that older age is associated with lower CR rates, highlighting the need for tailored treatment strategies that balance efficacy with the potential risks of intensive therapies in this population.

References

Acharya UH and Walter RB. Chimeric antigen receptor (CAR)-modified immune effector cell therapy for acute myeloid leukemia (AML). Cancers. 2020 Dec; 12(12): 3617. doi: 10.3390/cancers12123617. DOI: https://doi.org/10.3390/cancers12123617

Yamashita M, Dellorusso PV, Olson OC, Passegué E. Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis. Nature Reviews Cancer. 2020 Jul; 20(7): 365-82. doi: 10.1038/s41568-020-0260-3. DOI: https://doi.org/10.1038/s41568-020-0260-3

Tebbi CK. Etiology of acute leukemia: A review. Cancers. 2021 May; 13(9): 2256. doi: 10.3390/cancers13092256. DOI: https://doi.org/10.3390/cancers13092256

Raghupathi W and Raghupathi V. An empirical study of chronic diseases in the United States: a visual analytics approach to public health. International Journal of Environmental Research and Public Health. 2018 Mar; 15(3): 431. doi: 10.3390/ijerph15030431. DOI: https://doi.org/10.3390/ijerph15030431

De Kouchkovsky I and Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer Journal. 2016 Jul; 6(7): e441-. doi: 10.1038/bcj.2016.50. DOI: https://doi.org/10.1038/bcj.2016.50

Khan M, Altaf C, Malik HS, Naeem MA. Cytogenetic profile of Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia in Northern Pakistan. Pakistan Journal of Medical Sciences. 2023 Sep; 39(5): 1440. doi: 10.12669/pjms.39.5.6405. DOI: https://doi.org/10.12669/pjms.39.5.6405

Pimenta DB, Varela VA, Datoguia TS, Caraciolo VB, Lopes GH, Pereira WO. The bone marrow microenvironment mechanisms in acute myeloid leukemia. Frontiers in Cell and Developmental Biology. 2021 Nov; 9: 764698. doi: 10.3389/fcell.2021.764698. DOI: https://doi.org/10.3389/fcell.2021.764698

Watts J and Nimer S. Recent advances in the understanding and treatment of acute myeloid leukemia. F1000Research. 2018 Aug; 7. doi: 10.12688/f1000research.14116.1. DOI: https://doi.org/10.12688/f1000research.14116.1

Matza LS, Deger KA, Howell TA, Koetter K, Yeager AM, Hogge D et al. Health state utilities associated with treatment options for acute myeloid leukemia (AML). Journal of Medical Economics. 2019 Jun; 22(6): 567-76. doi: 10.1080/13696998.2019.1584108. DOI: https://doi.org/10.1080/13696998.2019.1584108

Ishii H and Yano S. New therapeutic strategies for adult acute myeloid leukemia. Cancers. 2022 Jun; 14(11): 2806. doi: 10.3390/cancers14112806. DOI: https://doi.org/10.3390/cancers14112806

Chen Y, Li J, Xu L, Găman MA, Zou Z. The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: From biology to therapeutic targeting. Cell Death Discovery. 2022 Sep; 8(1): 397. doi: 10.1038/s41420-022-01193-0. DOI: https://doi.org/10.1038/s41420-022-01193-0

Vundinti BR, Korgaonkar S, Dhangar S, Jijina F, Shanmukhaiah C. Frequency and pattern of chromosomal abnormalities in acute myeloid leukemia from Western India: A retrospective study. Journal of Cancer Research and Therapeutics. 2023 Jan; 19(2): 340-6. doi: 10.4103/jcrt.jcrt_393_22. DOI: https://doi.org/10.4103/jcrt.jcrt_393_22

Ciftciler R, Demiroglu H, Haznedaroglu IC, Sayınalp N, Aksu S, Ozcebe O et al. Impact of time between induction chemotherapy and complete remission on survival outcomes in patients with acute myeloid leukemia. Clinical Lymphoma Myeloma and Leukemia. 2019 Nov; 19(11): 729-34. doi: 10.1016/j.clml.2019.08.007. DOI: https://doi.org/10.1016/j.clml.2019.08.007

Manuprasad A, Raghavan V, Shenoy PK, Krishnan A, Nair CK. The utility of day 14 bone marrow response assessment in patients undergoing acute myeloid leukemia induction: A single institution retrospective experience. Cancer Research, Statistics and Treatment. 2021 Oct; 4(4): 628-33. doi: 10.4103/crst.crst_90_21. DOI: https://doi.org/10.4103/crst.crst_90_21

Shireen I, Komal S, Ansari AM, Meraj L. Frequency of complete remission after standard 3+ 7 induction therapy in patients with acute myeloid leukemia. Pakistan Journal of Medical Sciences. 2022 May; 38(5): 1138. doi: 10.12669/pjms.38.5.5249. DOI: https://doi.org/10.12669/pjms.38.5.5249

Zaki S, Burney IA, Khurshid M. Acute myeloid leukemia in children in Pakistan: an audit. Journal of Pakistan Medical Association. 2002 Jun; 52(6): 247-9.

Perera RA, de Silva HT, Gooneratne LV, Tudawe MN. Clinical features and haematological parameters at presentation in patients with acute leukaemia. 2008.

Abuelgasim KA, Albuhayri B, Munshi R, Al Mugairi A, Alahmari B, Gmati G et al. Impact of age and induction therapy on outcome of 180 adult patients with acute myeloid leukemia; retrospective analysis and literature review. Leukemia Research Reports. 2020 Jan; 14: 100206. doi: 10.1016/j.lrr.2020.100206. DOI: https://doi.org/10.1016/j.lrr.2020.100206

Yoon JH, Kim HJ, Kwak DH, Min GJ, Park SS, Jeon YW et al. Comparison of the effects of early intensified induction chemotherapy and standard 3+ 7 chemotherapy in adult patients with acute myeloid leukemia. Blood Research. 2017 Sep; 52(3): 174. doi: 10.5045/br.2017.52.3.174. DOI: https://doi.org/10.5045/br.2017.52.3.174

Hadisantoso DW, Ranuhardy D, Rajabto W, Rizka A, Setiawan L, Rinaldi I et al. Association of leukocyte nadir with complete remission in Indonesian acute myeloid leukemia patients undergoing 7+ 3 remission induction chemotherapy. F1000Research. 2022; 11. doi: 10.12688/f1000research.110320.2. DOI: https://doi.org/10.12688/f1000research.110320.2